Aristotle University Of Thessaloniki (AUTH)
Μελέτη του μοριακού μηχανισμού δράσης του αιθέριου ελαίου της μαστίχας που προκαλεί υπολιπιδαιμία
Abstract
dc:descriptionCardiovascular disease remains the leading cause of death worldwide. Central to the pathology of coronary heart disease is the accumulation of lipids, cholesterol and triglycerides, within the intima of arterial blood vessels. The search for drugs to treat dislipidemia remains a major pharmaceutical focus. In this study, we evaluated the hypolipidemic properties of the essential oil from Chios mastic gum (MGO). The hypolipidemic effect of MGO was investigated in naïve as well as in rats susceptible to detergent-induced hyperlipidemia. MGO administration into naïve rats resulted in a dose-dependent reduction in serum cholesterol and triglycerides levels. In hyperlipidemic rats, MGO treatment had also a strong hypolipidemic effect. By testing various components of MGO, we show for the first time that the hypolipidemic action is associated with camphene. Administration of camphene at a dose of 30 μg/g of body weight in hyperlipidemic rats resulted in a 54.5 % reduction of total cholesterol (p < 0.001), 54 % of LDL cholesterol (p < 0.001) and 34.5 % of triglycerides (p < 0.001). Treatment of HepG2 cells with camphene led to a decrease in cellular cholesterol content to the same extend as mevinolin, a known HMG-CoA reductase inhibitor. We showed that camphene lowers cholesterol and triglycerides in the plasma of hyperlipidemic rats without affecting HMG-CoA reductase activity, suggesting that its hypocholesterolemic and hypotriglyceridemic effects are associated with a mechanism of action different than that of statins. We examined the mechanism by which camphene exerts its hypolipidemic action. We evaluated the effect of camphene on the de novo synthesis of cholesterol and triglycerides from [14C]-acetate in HepG2 cells, along with the statin mevinolin. Camphene inhibited the biosynthesis of cholesterol in a dose dependent manner, and a maximal inhibition of 39 % was observed at 100 μΜ. Mevinolin reduced cholesterol biosynthesis levels up to 3 %. Interestingly, treatment with camphene reduced triglycerides levels by 34 % while mevinolin increased triglycerides levels by 26 %. Additionaly, camphene reduced fatty acid synthesis. Camphene also increased apolipoprotein-AI expression. We also examined the effects of camphene on the expression of SREBP-1, which affects the metabolism of triglycerides and SREBP-2, which mostly affects cholesterol synthesis. Interestingly, camphene increased the nuclear translocation of the mature form of SREBP-1 as it increased both the inactive precursor form and the mature. On the other hand, mevinolin was found to increase the amount of the mature form of SREBP-2. SREBP-1 expression was not affected by mevinolin. The effect of camphene is most likely regulated through SREBP-1, specifically SREBP-1c which is involved in regulating apolipoprotein secretion by affecting MTP levels in response to a decrease in the intracellular cholesterol. We propose that camphene up regulates SREBP-1 expression and MTP inhibition is likely to be a probable mechanism whereby camphene exerts its hypolipidemic effect. Given the critical role that the control of hyperlipidemia plays in cardiovascular disease, the results of our study provide insights into the use of camphene as an alternative lipid lowering agent and merits further evaluation.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vallianou, Ioanna
- Βαλλιάνου, Ιωάννα
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/30174